DA32 Life Science Tech Acquisition Corp.
Cash in trust
$204.5M
$204,493,113
Trust per share
$10.16
Redemption value
IPO
Jul 2021
$200.0M raised
Combination deadline
—
Not disclosed
Filings on record
77
Latest Feb 7, 2024
Overview
DA32 Life Science Tech Acquisition Corp. is a special purpose acquisition company incorporated in Delaware and registered with the SEC under CIK 0001863294. It completed its initial public offering in Jul 2021, raising $200.0M in gross proceeds. The vehicle is sponsored by DA32 through DA32 Sponsor LLC. The mandate targets technology, healthcare. Deadline lapsed without a deal; trust returned to public shareholders.
“we intend to focus our search for business combination targets in four separate areas of the larger life sciences industry, including: Life Sciences Tools : Advances in biology, genomics and proteomics, automation, digitization, optics and other technologies have accelerated an expanding sector of life science tools companies.”
Reading the filings
Arithmetic on what DA32 Life Science Tech Acquisition Corp. has disclosed, written the way a desk would read it. These are observations, not a rating. Nothing here scores the vehicle or implies a view on it.
Trust versus the $10 unit
The trust holds $10.16 per public share, 1.6% above the $10.00 the units were sold at. That spread is accrued interest on the trust and, where the charter provides for it, sponsor contributions paid in to buy more time. It is the floor a public shareholder can redeem at, not a valuation of the business.
Underwriting
J.P. Morgan led the offering. It has been named on 41 SPAC IPOs, book-running 30 of them, and 2.5% of its resolved vehicles closed a deal. The syndicate has no control over whether a sponsor finds a target, but the quality of the book at pricing shapes who ends up holding the units.
SEC filing history
Free tier: filings older than 24 hours- SC 13G/A
FORM SC 13G/A
Accession 0001062993-24-002182
- SC 13G/A
13G/A DALS
Accession 0001682021-23-000010
- 4
Statement of changes in beneficial ownership
Accession 0001062993-23-016234
- 4
Statement of changes in beneficial ownership
Accession 0001062993-23-016233
- SC 13G/A
Amended beneficial ownership report (passive)
Accession 0001306550-23-009689
- 15-12G
Deregistration of securities
Accession 0001193125-23-205131
- SC 13D/A
ARCH VENTURE FUND XI, L.P. - DA32 LIFE SCIENCE -- SCH 13G/A(#1)
Accession 0001072613-23-000410
- SC 13D/A
SC 13D/A
Accession 0001193125-23-201720
- 4
Statement of changes in beneficial ownership
Accession 0001193805-23-001041
- SC 13D/A
Amended beneficial ownership report (activist)
Accession 0001193805-23-001040
- SC 13D/A
SC 13D/A
Accession 0001193125-23-200553
- 25-NSE
Notification of delisting
Accession 0001354457-23-000548
- 8-K
Regulation FD disclosure
Items 7.01, 9.01 · Accession 0001193125-23-191376
- SC 13G/A
SC 13G/A
Accession 0001104659-23-060911
- 10-Q
Quarterly report
Accession 0001193125-23-143535
- SC 13G
Beneficial ownership report (passive)
Accession 0001604488-23-000104
- 10-K
Annual report
Accession 0001193125-23-083849
- SC 13G/A
FORM SC 13G/A
Accession 0001062993-23-003091
- SC 13G/A
Amended beneficial ownership report (passive)
Accession 0001678858-23-000001
- SC 13G/A
Amended beneficial ownership report (passive)
Accession 0001040188-23-000051
- SC 13G/A
Amended beneficial ownership report (passive)
Accession 0001306550-23-005110
- 10-Q
Quarterly report
Accession 0001193125-22-282602
- 10-Q
Quarterly report
Accession 0001193125-22-221227
- 10-Q
Quarterly report
Accession 0001193125-22-150065
- 10-K
Annual report
Accession 0001193125-22-091916
- SC 13G/A
Amended beneficial ownership report (passive)
Accession 0000902219-22-000014
- SC 13G
Beneficial ownership report (passive)
Accession 0001062993-22-002860
- SC 13G
Beneficial ownership report (passive)
Accession 0000834237-22-007205
- SC 13G/A
Amended beneficial ownership report (passive)
Accession 0001678858-22-000132
- SC 13G/A
Amended beneficial ownership report (passive)
Accession 0001678858-22-000001
DA32 Life Science Tech Acquisition Corp.: questions answered
What is DA32 Life Science Tech Acquisition Corp.?
DA32 Life Science Tech Acquisition Corp. is a special purpose acquisition company incorporated in Delaware and registered with the SEC under CIK 0001863294. It completed its initial public offering in Jul 2021, raising $200.0M in gross proceeds. The vehicle is sponsored by DA32 through DA32 Sponsor LLC. The mandate targets technology, healthcare. Deadline lapsed without a deal; trust returned to public shareholders.
How much does DA32 Life Science Tech Acquisition Corp. hold in trust?
Approximately $204,493,113, or about $10.16 per public share, as at the most recent filing on record. Trust balances move: shareholders redeem at extension votes and at the combination vote, and sponsors pay contributions in to extend. Treat the figure as a point-in-time disclosure, not a running balance.
When must DA32 Life Science Tech Acquisition Corp. complete a merger?
No combination deadline appears in the filings we have indexed. The date is stated in the charter and repeated in each quarterly report; where our parser could not establish it with confidence we leave it blank rather than infer one.
What happens if DA32 Life Science Tech Acquisition Corp. does not find a target in time?
The charter requires the vehicle to redeem 100% of the public shares and return the trust, pro rata, to public shareholders. That is the mechanism working as designed rather than a default. Founder shares and warrants are worthless in that outcome, which is why the sponsor's incentive is to get a deal done or to buy more time. Across the market, deadline lapsed without a deal; trust returned to public shareholders.
Can I redeem shares in DA32 Life Science Tech Acquisition Corp., and at what price?
Public shareholders may elect to redeem in connection with a combination vote and at each extension vote, at the pro-rata trust value on the relevant record date, most recently disclosed at about $10.16 per share. Redemption is a right attached to the public shares only; warrants and rights carry no claim on the trust. The mechanics and the deadline for electing are set out in the proxy statement for the vote in question.
Is the trust value the same as the share price for DA32 Life Science Tech Acquisition Corp.?
No. Trust per share is a disclosed, contractual figure: what a redeeming holder receives. The market price is whatever the shares change hands at, which can sit above the trust when a deal is well received or below it when the market doubts one will close. We do not have a current quote for this vehicle, so no spread is shown.
Who sponsors DA32 Life Science Tech Acquisition Corp., and what is their track record?
DA32 Sponsor LLC is the sponsor entity, part of the DA32 franchise. This is the only vehicle we have attributed to that sponsor.
Which banks underwrote the DA32 Life Science Tech Acquisition Corp. IPO?
J.P. Morgan, Cowen. J.P. Morgan and Cowen were credited as book-running managers on the cover. Syndicate membership and role are read from the prospectus cover and the underwriting section.
Is DA32 Life Science Tech Acquisition Corp. a good investment?
That is not a question this site answers. DA32 Life Science Tech Acquisition Corp. is covered here as reference data: what the company filed, when it filed it, and what the numbers in those filings say. The Edge, FOMO and Potential scores on this page are derived measures with a published formula, not ratings of investment merit: they describe the setup, and every component is shown so you can take them apart. We publish no price targets and no recommendations, and nothing here should be read as advice. The figures are a starting point for your own work, and each one carries the accession number of the filing it came from.
Where does this DA32 Life Science Tech Acquisition Corp. data come from?
Filings DA32 Life Science Tech Acquisition Corp. submitted to the SEC under CIK 0001863294: the registration statement and final prospectus for the structure, quarterly and annual reports for the trust, current reports and proxy statements for deals, votes and extensions. Trust economics are taken from the registrant's own XBRL tags rather than parsed from prose, which is why they are exact. Every filing in the history above is listed with its accession number, which identifies the document uniquely on EDGAR; Pro accounts open it directly from the row.
Compiled by the SPACListing research desk
Last reconciled Sep 4, 2026
Every figure on this page is read from documents the registrants filed with the U.S. Securities and Exchange Commission, principally the IPO prospectus (Form 424B4), quarterly and annual reports, current reports and proxy statements, the registrant's own XBRL tags for trust economics. Nothing is sourced from press coverage, from the companies themselves, or from a third-party aggregator. Where a filing does not disclose something, the field is left blank rather than estimated.
Read the full methodology · What is in the dataset · Report a correction
SPACListing is a reference-data service, not an investment adviser. Nothing here is a recommendation to buy or sell any security.
Continue reading
The context around this vehicle: who else the sponsor has launched, which banks priced it, and where it sits in the wider market.
DA32: the full record
Every vehicle this sponsor has launched, what closed, what liquidated and what is still live.
J.P. Morgan in SPACs
Mandates, bookrun credit, deal volume and the outcome of the vehicles it priced.
Technology SPACs
Every vehicle chasing the same mandate, ranked by cash in trust.
All liquidated spacs
Deadline lapsed without a deal; trust returned to public shareholders.
Deadline calendar
Which sponsors are running out of time, and when the extension votes land.
What is a SPAC?
The structure, the economics and where the risks actually sit.
SPAC glossary
Every term in a blank-check filing, defined the way practitioners use it.
How this data is built
Coverage universe, ingestion, normalisation, lifecycle classification and known limits.